"Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene (All-patient Surveillance)"

CompletedOBSERVATIONAL

Enrollment

3,091

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Advanced or Recurrent Colorectal Cancer

Interventions

DRUG

Panitumumab

Panitumumab for intravenous infusion